Glycogen synthase kinase-3 (GSK3) is a constitutively active protein kinase in brain. Increasing evidence has shown that GSK3 acts as a modulator in the serotonin neurotransmission system, including direct interaction with serotonin 1B (5-HT1B) receptors in a highly selective manner and prominent modulating effect on 5-HT1B receptor activity. In this study, we utilized the serotonin neuron-selective GSK3b knockout (snGSK3b-KO) mice to test if GSK3b in serotonin neurons selectively modulates 5-HT1B autoreceptor activity and function. The snGSK3b-KO mice were generated by crossbreeding GSK3b-floxed mice and ePet1-Cre mice. These mice had normal growth and physiological characteristics, similar numbers of tryptophan hydroxylase-2 (TpH2)-expressing serotonin neurons, and the same brain serotonin content as in littermate wild type mice. However, the expression of GSK3b in snGSK3b-KO mice was diminished in TpH2-expressing serotonin neurons. Compared to littermate wild type mice, snGSK3b-KO mice had a reduced response to the 5-HT1B receptor agonist anpirtoline in the regulation of serotonergic neuron firing, cAMP production, and serotonin release, whereas these animals displayed a normal response to the 5-HT1A receptor agonist 8-OH-DPAT. The effect of anpirtoline on the horizontal, center, and vertical activities in the open field test was differentially affected by GSK3b depletion in serotonin neurons, wherein vertical activity, but not horizontal activity, was significantly altered in snGSK3b-KO mice. In addition, there was an enhanced anti-immobility response to anpirtoline in the tail suspension test in snGSK3b-KO mice. Therefore, results of this study demonstrated a serotonin neuron-targeting function of GSK3b by regulating 5-HT1B autoreceptors, which impacts serotonergic neuron firing, serotonin release, and serotonin-regulated behaviors.
Introduction
Glycogen synthase kinase-3 (GSK3) [1] is widely distributed in brain [2] and is an influential enzyme in many aspects of neuronal function [3, 4] . Unlike other protein kinases, GSK3 is highly active under resting conditions, and undergoes inhibitory regulation upon cellular stimulation, such as by neurotrophins and several neurotransmitters [5, 6, 7] . Cumulative evidence from in vitro measurements, pharmacological studies, and animal behavioral tests strongly supports GSK3 as an integrative mediator of serotonin neurotransmission [8] . GSK3 is also a prominent pharmacological target of major psychotropic drugs, including lithium [9, 10] , serotonin-modulating antidepressants [5, 11] , and antipsychotics [12, 13, 14] , all of which act directly or indirectly to suppress GSK3 activity.
As a protein kinase, GSK3 phosphorylates many protein substrates that distribute in both neural and peripheral tissues [3, 15] . The two isoforms of GSK3, GSK3a and GSK3b [16] , are subject to similar regulation but may have distinguishable functions [17, 18, 19, 20] . As a result, in vivo activation or inhibition of GSK3a and GSK3b can have a variety of physiological effects. Thus, identifying GSK3 substrates that have specific functions in brain circuits could be critical in understanding the neurological actions of GSK3 and developing GSK3-targeting therapeutics.
We have identified GSK3b, but not GSK3a, as a direct modulator of 5-HT1B receptors [21, 22] . Both human and mouse 5-HT1B receptors contain eight GSK3 consensus phosphorylation sites [23] that locate in intracellular loops 1, 2, and 3 of the G protein-coupled receptor (GPCR) [8, 22] . In contrast, the highly homologous 5-HT1A receptors have no GSK3 consensus sites in intracellular loops 1 and 2, and the two sites in intracellular loop-3 of human 5-HT1A receptors are not homologous with mouse 5-HT1A receptors. In cultured heterologous cells expressing 5-HT1B or 5-HT1A receptors, GSK3b directly associates with 5-HT1B receptors at the [pS(154)AKRpT(158)] sequence located in the i2-loop [22] . GSK3b acts as a signal pathway-selective modulator of 5-HT1B receptors [21] . Disrupting the interaction between 5-HT1B receptors and GSK3b by mutagenesis or GSK3 inhibitors effectively abolishes the coupling of Gia2 to receptors [21] and serotonin-induced inhibition of cAMP [22] , but not receptor recruitment of b-arrestin2 [22] . The effect of GSK3b on 5-HT1B receptors is to facilitate receptor activity, which is opposite to other GPCR-regulating protein kinases (GRKs) that typically desensitize and terminate GPCR activity [24] . This is a highly selective function of GSK3b, as it does not alter regulation of Gia2 and cAMP by 5-HT1A receptors [21, 22] .
In mouse brain tissues, pre-treatment of cortical slices with GSK3 inhibitors completely abolishes the inhibitory effect of 5-HT1B receptors on potassium-evoked 3 H-serotonin release [21] , a characteristic function of 5-HT1B autoreceptors in the axon terminals of serotonin neurons [25, 26, 27] . GSK3 inhibitors also facilitate the anti-immobility effect of 5-HT1B receptor agonist in the tail suspension test [21] , but has little effect in 5-HT1B receptor agonist-induced increase in horizontal activity in the open field, suggesting that GSK3 has differential effects in modulating 5-HT1B receptor-regulated behaviors.
5-HT1B receptors share high protein sequence homology and signal transduction processes with 5-HT1A receptors, and both act as autoreceptors and heteroreceptors in the brain [28, 29, 30, 31] . Different from 5-HT1A autoreceptors that are located in the somatodendrites to reduce neuron firing and serotonin output [27] , 5-HT1B autoreceptors are primarily located on the serotonin neuron axon terminals that extend to other brain regions. Upon activation, 5-HT1B autoreceptors cause a strong feedback inhibition of serotonin release [27] . Meanwhile, 5-HT1B receptors also act as heteroreceptors in several brain regions to control release of other neurotransmitters [26] , rendering complex physiological and behavioral effects. Therefore, to further understand the functional impact of GSK3b, that is also widely distributed in brain, in modulating 5-HT1B receptors, it is important to dissect the function of GSK3b in regulating 5-HT1B autoreceptors separately from its heteroreceptors. In this study, we utilized serotonin neuron-selective GSK3b knockout (snGSK3b-KO) mice to examine the effect of GSK3b on 5-HT1B autoreceptors.
Results

Serotonin neuron-selective GSK3b knockout (snGSK3b-KO) mice
To study the function of GSK3b in serotonin neurons, GSK3b was selectively deleted from serotonin neurons (snGSK3b-KO mice) by crossbreeding GSK3b-flox/flox mice [32] with ePet1-Cre mice [33] . Homozygous male snGSK3b-KO mice and littermate WT mice were selected by tail DNA genotyping of offsprings of GSK3b-flox/flox and GSK3b-flox/flox:ePet1-Cre mating pairs ( Figure 1A ).
TpH2-containing serotonin neurons were visible in the midbrain raphe nucleus in both WT and snGSK3b-KO mice ( Figure 1B) . Quantification of TpH2-positive neurons in the ventral, dorsal, and dorsal lateral raphe nucleus of the midbrain showed that the numbers of serotonin neurons were almost the same in WT and in snGSK3b-KO mice (Student's t-test; t(7) VRN = 20.497, t(6) DRN = 20.237, t(6) DLRN = 0.221; p.0.05 for all; Figure 1B, 1C) . In contrast, GSK3b immunostaining in the same raphe areas was stronger in WT mice than in snGSK3b-KO mice ( Figure 1B, 1C) . Quantification of GSK3b and TpH2 co-immunostained neurons as the percentage of total TpH2-positive neurons in the ventral, dorsal, and dorsal lateral raphe nucleus of snGSK3b-KO mice showed a significant reduction to approximately 65%, 85%, and 80%, respectively, when compared to WT mice (Student's t-test; t(7) VRN = 9.39, t(6) DRN = 10.63, t(3) DLRN = 8.90; p,0.05 for all; Figure 1B, 1C) . It was noted that some GSK3b-positive cells remained in the raphe area ( Figure 1B) , which may represent either non-complete GSK3b knockout in some TpH2-positive neurons, GSK3b in Pet1 non-expressing cells, or GSK3b in non-serotonergic cells. GSK3b immunostaining in the cerebral cortex did not identify a remarkable difference between WT and snGSK3b-KO mice ( Figure 1B) .
Unlike the global knockout of GSK3b that is lethal to animals [34] , all snGSK3b-KO mice lived into adulthood when they were used for experiments (8-14 weeks old). Continued observation also showed that both male and female snGSK3b-KO breeders survived beyond 9 months of age. Body weight and body temperature recorded during 4-12 weeks of age showed no significant differences between snGSK3b-KO and WT mice (mixed models; the main effects and interaction for body weight are F (1, 170) Figure 1D ). Defecation recorded at 12 weeks of age also had no significant difference between snGSK3b-KO and WT mice (Student's t-test; t(30) def = 0.29, p = 0.7758; Figure 1D ). snGSK3b-KO mice performed normally as WT littermates in the Rotarod test (Student's t-test; t(6) Rotarod = 21.47, p = 0.1926; Figure 1D ). Therefore, snGSK3b-KO mice appeared relatively normal compared to their littermate WT controls.
To ensure that deletion of GSK3b expression in raphe neurons did not lead to serotonin depletion in the brain, we used quantitative near-infrared immunofluorescence imaging [35] to measure relative fold variations in serotonin levels between mice of different genotypes. This approach allowed us to quantify reductions of 60-80% in serotonin levels in all tested brain areas ( Figure 2A ) of mice expressing a R439H loss-of-function mutant form of TpH2 ( Figure 2B ), which is comparable to the fold-change obtained by HPLC measurement in these mice [11] . In contrast, no reduction of serotonin levels was observed between WT and snGSK3b-KO mice ( Figure 2C ), and therefore suggesting that inactivation of GSK3b does not cause overt deficiencies of serotonin neurons and their capacity to synthesize serotonin.
Dorsal raphe serotonin neuron firing in snGSK3b-KO mice
To test the effect of GSK3b on serotonergic neuronal activity, we used loose-patch electrophysiological recordings of serotonin neurons in the dorsal raphe nucleus (DRN) of WT and snGSK3b-KO mice. Serotonin neurons were selected for recording based on a 50% or greater reduction in spontaneous action potential frequency following a 2 min treatment of serotonin (40 mM) [36] . The mean spontaneous action potential frequency of serotonin neurons from snGSK3b-KO mice at baseline was twice the mean baseline firing rate of neurons from WT mice (Student's t-test; t(17) = 2.45, p,0.05; Figure 3A ). Serotonin application silenced neuronal firing equally in both genotypes ( Figure 3A) . Furthermore, both WT and snGSK3b-KO neurons were completely silenced by the 5-HT1A receptor agonist, 8-OH-DPAT (1 mM) ( Figure 3B ). Unlike serotonin and 8-OH-DPAT, 2 min application of the 5-HT1B receptor agonist anpirtoline had no effect on the spontaneous firing of WT serotonin neurons in the DRN ( Figure 3B) .
In order to test the effect of GSK3b on 5-HT1B autoreceptor activity in the DRN serotonin neurons, we next used a high concentration of potassium chloride (KCl, 10 mM) to depolarize neurons [37] prior to application of anpirtoline. A two-way repeated measures ANOVA (Genotype X Time) of the firing rate following 1-and 2-min application of potassium revealed significant main effects of genotype, time, and a significant interaction (F(1,17) = 5.71, F(1,17) = 17.26, and F(1,17) = 9.49, respectively; p,0.05 for all). Specifically, the higher concentration of potassium increased neuronal firing of snGSK3b-KO neurons by 29% and 58% above baseline after 1 and 2 min of exposure, respectively, but did not significantly increase the firing rate above baseline activity in WT neurons (Sidak post hoc, p,0.05; Figure 3C , 2D). Unlike spontaneous neuronal firing, however, high potassium-induced neuron firing was significantly suppressed upon activation of 5-HT1B receptors by anpirtoline in WT neurons, whereas the response to anpirtoline was significantly diminished in snGSK3b-KO neurons (two-way ANOVA; main effects of Genotype and Time, F(1,17) = 5.42, p,0.05 and F(1,17) = 14.14, p,0.05, respectively, but the interaction failed to reach significance, F(1,17) = 3.16, p = 0.092; Figure 3C -3E).
3. Regulation of forskolin-stimulated cAMP by 5-HT1 receptors in the cerebral cortex of snGSK3b-KO mice Both 5-HT1B and 5-HT1A receptors couple to Gi proteinlinked inhibition of cAMP [38] , and we have previously shown that inhibition of GSK3b in cells and brain slices abolishes 5-HT1B receptor-, but not 5-HT1A receptor-induced inhibition of cAMP production [21, 22] . To test if selective deletion of GSK3b from serotonin neurons affects cAMP production, we measured forskolin-stimulated cAMP production in the cerebral cortex that is innervated by serotonergic axons. In the WT cortical slices, both the 5-HT1B receptor agonist anpirtoline and the 5-HT1A receptor agonist 8-OH-DPAT reduced forskolin-stimulated cAMP production (one way ANOVA; F(7,18) = 104.32, p,0.001; LSD post hoc; Figure 4A ). The effect of anpirtoline was blocked by the [67] . (B) Imaging of serotonin immunofluorescence signal and quantification of relative changes in serotonin content in sagital brain section of TpH2 R439H mice along with sections from the corresponding littermate WT control analyzed within the same scan. (C) Imaging of serotonin immunofluorescence signal and quantification of relative changes in serotonin content in snGSK3b-KO mice along with sections from its corresponding littermate WT control analyzed within the same scan. Average signal value for WT control animals was normalized to 100%, data are mean 6 SEM from six sections per genotype. p#0.05*, 0.01** or 0.005*** in Student's t-test when each mutant genotype was compared to its corresponding littermate WT mice. doi:10.1371/journal.pone.0043262.g002 GSK-3beta in Serotonin Neurons PLOS ONE | www.plosone.org5-HT1B receptor antagonist SB224289 (LSD post hoc, p,0.05; Figure 4A ), but not by the 5-HT1A receptor antagonist WAY100635 (LSD post hoc, p.0.05; Figure 4A ), whereas the effect of 8-OH-DPAT was blocked by WAY100635 (LSD post hoc, p,0.05; Figure 4A ) but not by SB224289 (LSD post hoc, p.0.05; Figure 4A ), confirming the selective effects of anpirtoline and 8-OH-DPAT on 5-HT1B receptors and 5-HT1A receptors, respectively. In WT mice, the effect of anpirtoline on forskolinstimulated cAMP was concentration-dependent, with 2 mM causing 50% reduction, and 10 mM achieving near maximal inhibition (twoway ANOVA; F(3,25) treatment = 1415.91, F(1,25) genotype = 307.78, and F(3,25) interaction = 141.08, p,0.0001 for all effects; LSD post hoc, p,0.05; Figure 4B , left panel). In snGSK3b-KO mice, a low concentration of anpirtoline (2 mM) was able to reduce 50% of cAMP production (two-way ANOVA; LSD post hoc, p,0.05; Figure 4B , left panel), similar to the WT mice. However, the effect of anpirtoline plateaued at 2 mM, and higher concentrations of this compound were unable to elicit additional inhibition (LSD post hoc; p.0.05; Figure 4B , left panel). In contrast to the limited effect of anpirtoline in snGSK3b-KO mice, 8-OH-DPAT effectively caused concentration-dependent inhibition of forskolin-stimulated cAMP production in both WT and snGSK3b-KO mice, and this effect was the same in both genotypes (two-way ANOVA; F (3, 25) 
Regulation of serotonin release by 5-HT1 receptors in the cerebral cortex of snGSK3b-KO mice
A characteristic function of 5HT1 autoreceptors is to negatively regulate serotonin release [26, 27] , and GSK3 inhibitors were able to reverse the inhibitory effect of the 5-HT1B receptor agonist anpirtoline on potassium-evoked [ 3 H]-serotonin release [21] . Here, we tested whether selective deletion of GSK3b from serotonin neurons alters 5-HT1B and 5-HT1A autoreceptorregulated serotonin release in the cerebral cortical slices. In the absence of 5-HT1B or 5-HT1A receptor agonists, potassiumevoked 3 H-serotonin release was almost identical in the cortical slices of WT and snGSK3b-KO mice ( Figure 5A ). In WT mice, anpirtoline caused a significant 33% reduction of potassiumevoked serotonin release. In contrast, anpirtoline only caused a 17% reduction of serotonin release in snGSK3b-KO mice, significantly less than in WT mice (F(2,26) treatment = 13.31, p,0.0001; F(1,26) genotype = 5.11, p = 0.032, F(2,26) interaction = 1.378, p = 0.27 respectively; Figure 5B ). The 5-HT1A receptor agonist 8-OH-DPAT also caused a less robust, but significant 22% reduction of serotonin release in WT mice. This small effect was retained in snGSK3b-KO mice where 8-OH-DPAT caused a 20% reduction of serotonin release.
Regulation of open field activity by 5-HT1 receptors in snGSK3b-KO mice
Activation of 5-HT1B receptors is associated with elevated locomotor activity, which is often measured by the horizontal activity in the open field [39, 40] . When this activity was tested in the WT and snGSK3b-KO mice, baseline activity did not differ between the two genotypes. Systemically administered anpirtoline (4 mg/kg, i.p.) induced a significant increase in total horizontal travel distance, and this effect of anpirtoline was similar in WT and snGSK3b-KO mice (two way ANOVA; F (1,16) Another behavioral component in the open field is vertical activity, which has been used to monitor behaviors related to exploration or anxiety [41] . The time course showed that baseline vertical activity varied at each recorded time point in both genotypes. While there was an observable tendency for anpirtoline to cause a sustained reduction in vertical activity throughout the 30 min treatment ( Figure 6C , upper left panel), the effect of anpirtoline in snGSK3b-KO mice appeared to include a robust increase in the initial vertical activity followed by a transient reduction of activity that did not sustain. To summarize the overall effect of anpirtoline in vertical activity, we analyzed the ratio of overall post-treatment to pre-treatment effect. The vertical activity in saline-treated animals was similar between WT and snGSK3b-KO mice. Anpirtoline significantly reduced overall vertical activity Figure 6C , lower right panel). Therefore, vertical activity was similarly suppressed by 5-HT1B and 5-HT1A receptors, but GSK3b in serotonin neurons only influences the effect of 5-HT1B receptor-, not 5-HT1A receptor-regulated vertical activity.
6. Effect of anpirtoline on tail suspension test (TST) in snGSK3b-KO mice 5-HT1B receptor agonists can reduce immobility in TST [42, 43] , and we previously found that GSK3 inhibitors intensified the anti-immobility effect of anpirtoline in TST [21] . However, intracerebroventricular administered GSK3 inhibitors would inhibit GSK3 in all surrounding neurons with little selectivity for specific neuron types. Here, we tested if deletion of GSK3b in serotonin neurons enhances the anti-immobility effect of anpirtoline in snGSK3b-KO mice. In WT mice, a relatively low dose of anpirtoline (4 mg/kg, i.p.) did not cause a significant reduction in immobility in TST (Figure 7) . In snGSK3b-KO mice, the baseline TST immobility time was almost identical to that of WT mice (twoway ANOVA; F(1,50) genotype = 1.92, p = 0.1718; F(2,50) block = 8.09, p = 0.0009; F(2,50) interaction = 0.37, p = 0.6926; Figure 7) . However, the same dose of anpirtoline caused 20% reduction of immobility in snGSK3b-KO mice, which was a significant anti-immobility effect comparing to baseline immobility in snGSK3b-KO mice (two-way ANOVA; F (1, 47) 
Discussion
The results of this study demonstrate that GSK3b modulates serotonin neuron function. This study showed that one of its effects in serotonin neurons is to selectively modulate activity of 5-HT1B autoreceptors that impact 5-HT1B receptor-regulated serotonin neuron firing, cAMP production, serotonin release, and behaviors. Observation of this study, however, does not exclude that the multi-functional GSK3b may also affect other functions of serotonin neurons, which remain to be investigated.
The serotonin neuron-selective GSK3b knockout is the first model to specifically delete GSK3b in a single type of neurons in the central serotonin system. It provides a tool to sort out the effect of GSK3b on type 1 serotonin autoreceptors that attribute to the complex physiological and behavioral actions of serotonin. In this study, we focused on the beta-isoform of GSK3 (GSK3b) because we previously established that GSK3b is a direct modulator of 5-HT1B receptors, whereas GSK3a has little effect on 5-HT1B receptors [21, 22] . In earlier studies, complete inactivation of GSK3b was found to cause late embryonic lethality [34] , but GSK3b knockout by tissue-selective recombination of floxed GSK3b, such as in the liver [32] and the renal collecting duct [44] , does not profoundly affect survival. We therefore utilized GSK3b-floxed animals to develop snGSK3b-KO mice. We elected to use ePet1-directed Cre recombinase [33] to delete GSK3b in serotonin neurons because Pet1 ETS gene expression is restricted in the entire rostrocaudal extent of serotonergic hindbrain raphe nuclei, and Pet1 RNA colocalizes with TpH2-positive neurons but not with non-serotonergic cells in raphe nuclei [45, 46] . The reduction of GSK3b expression in TpH2-expressing serotoninsynthesizing neurons was significant when tested by immunohistochemistry, but GSK3b was not completely deleted from the midbrain raphe. The residual GSK3b in raphe could be due to expression in Pet-1 non-expressing serotonin neurons or in nonserotonin cells, or due to an incomplete knockout of GSK3b in serotonin neurons, which remains to be determined. GSK3b expression in the cerebral cortex was not significantly changed in snGSK3b-KO mice, which is likely due to the scattered axon distribution of small numbers of serotonin neurons in brain areas outside the raphe nucleus. We also did not detect a difference of the expression of 5-HT1B and 5-HT1A receptors in the midbrain and cerebral cortex (data not shown). Although we could not rule out technical limitations of separating serotonin autoreceptors from heteroreceptors in these brain regions, in our previous reports [21, 22] , GSK3 inhibitors or knock-down of GSK3b significantly altered the activity of 5-HT1B receptors when the level of exogenously expressed 5-HT1B receptors remains the same. The similarities in serotonin neuron numbers, brain serotonin content, potassium-evoked serotonin release, animal survival, physiological conditions, and basic movement between WT and snGSK3b-KO mice suggest that embryonic deletion of GSK3b does not grossly affect the presence of serotonin neurons, serotonin synthesis capacity, and some basic functions of serotonin. Since Pet-1 expresses in serotonin neurons at embryonic day-12.5, one day prior to the onset of serotonin synthesis in these cells [45] , knockout GSK3b at this stage of development may not significantly affect formation of serotonin neuron. This would be different from systemic GSK3b knockout that has no GSK3b expression at the beginning of neuron development [34] . Alternatively, the remaining GSK3a in these neurons may compensate for the basal activity of GSK3 in serotonin neurons. The new snGSK3b-KO mouse model is thus suitable to address the central question of this study -the impact of GSK3b on 5-HT1 autoreceptor activity.
In this study, electrophysiological recording of serotonin neuron firing revealed a specific modulating effect of GSK3b. The basal serotonin neuronal firing rate is higher in snGSK3b-KO mice in both physiological and high potassium conditions, which is likely the first evidence showing that active GSK3b contributes to the threshold of serotonergic neuronal activity under physiological conditions. It also raises the possibility that during pathological conditions with GSK3b hyperactivity, which may occur when the inhibitory control of GSK3b is impaired in neuropsychiatric disorders [47] , appropriate therapeutic inhibition of GSK3b may restore serotonergic neuronal activity. The complete suppression of spontaneous serotonin neuron firing by serotonin and 5-HT1A receptor activation [48] was not altered by deleting GSK3b, which is in agreement with our molecular studies showing that activation of 5-HT1A receptors is not GSK3b-dependent [21, 22] . The underlying mechanism for the inability of 5-HT1B receptor activation to alter the basal spontaneous serotonin neuron firing is not clear, but we speculate that the axon terminal 5-HT1B autoreceptors are likely involved in regulating active serotonin neuron firing. High potassium was applied to depolarize neurons [37] , and as shown it increased serotonin neuron firing, which then allowed measurement of 5-HT1B autoreceptor-induced negative regulation of neuron firing and to test whether GSK3b influenced the effect of active 5-HT1B autoreceptors. Since potassium-induced serotonin neuron firing was higher in snGSK3b-KO mice, we calculated the effect of anpirtoline as a percentage of the baseline firing rate. Indeed, a diminished effect of anpirtoline in snGSK3b-KO mice suggests that the effect of 5-HT1B autoreceptors on serotonin neuron activity in the high potassium condition is modulated by GSK3b.
In our previous studies, 5-HT1B receptor-induced inhibition of cAMP production in cerebral cortical slices was abolished by treatment with GSK3 inhibitors [21, 22] . Somewhat unexpectedly, the effect of a low concentration of anpirtoline on cAMP was not altered in snGSK3b-KO mice, whereas the effects of higher concentrations of anpirtoline were reduced. Our antagonist experiment confirmed that the higher concentrations of anpirtoline used in the study were selective to 5-HT1B receptors, and thus, this is likely an effect of GSK3b on 5-HT1B autoreceptors. However, since cAMP measured in cortical slices includes cAMP produced by all types of cells, and there are 5-HT1B autoreceptors and heteroreceptors in the cerebral cortex, this is not a serotonin neuron-specific measurement. Therefore, the lack of effect seen at lower concentration of anpirtoline may be due to activation of 5-HT1B heteroreceptors located in other types of cells that retain normal expression of GSK3b. Alternatively, a subtype of high affinity 5-HT1B autoreceptors may exist in serotonin neurons, the activity of which is independent of GSK3b. Nevertheless, the significantly reduced response to higher concentrations of anpirtoline in snGSK3b-KO mice is in support of a modulating effect of GSK3b on 5-HT1B autoreceptors in serotonin neurons. Likewise, the unaltered response of cAMP to the 5-HT1A receptor agonist 8-OH-DPAT in snGSK3b-KO mice provides additional evidence that GSK3b selectively modulates the activity of 5-HT1B autoreceptors and not 5-HT1A autoreceptors.
Regulation of serotonin release is a specific function of serotonin neurons, and we have previously found that GSK3 inhibitors were able to abolish anpirtoline-induced inhibition of potassium-evoked serotonin release in cortical slices [21] . The reduced effect of anpirtoline on serotonin release in snGSK3b-KO mice was less robust than GSK3 inhibitors, which may be explained by incomplete knockout of GSK3b in some serotonin neurons as shown in Figure 1 , but this effect on 5-HT1B autoreceptors was substantially different from that on 5-HT1A autoreceptors as 8-OH-DPAT-induced inhibition of serotonin release in cortical slices was not altered in snGSK3b-KO mice. Since activation of 5-HT1B autoreceptors causes negative feedback inhibition of serotonin release, deleting GSK3b from serotonin neurons could potentially reduce the activity of 5-HT1B autoreceptors and thus maintain sufficient serotonin supply in synapses to regulate functions of other neurons.
With the mechanistic model presented in this study, it appears that GSK3b has little interaction with 5-HT1A receptors. It should be clarified that 5-HT1A receptors can regulate GSK3b activity in mouse brain, wherein activation of 5-HT1A receptors results in phosphorylation of GSK3b at its serine-9 residue [5, 49] and therefore, inactivation of GSK3b [23] . The potential impact of GSK3b in mediating 5-HT1A autoreceptor signaling in serotonin neurons has not been studied, but the snGSK3b-KO mouse model is not designed to study this role of GSK3b because GSK3b is abolished in these mice, thus GSK3b-dependent 5-HT1A autoreceptor actions may have been maximized, instead of diminished [8] .
In animal models, 5-HT1B receptors have effects in regulating behaviors relevant to mood, anxiety, hyperactivity, aggression, reward, perseveration, and cognition [26, 50, 51, 52, 53] . However, the behavioral effects of 5-HT1B receptors are diversely mediated by their autoreceptors and heteroreceptors [26] , which appears to be a major challenge in understanding the behavioral effects of brain 5-HT1B receptors. Since the snGSK3b-KO mouse model only deletes GSK3b in serotonin neurons, it allows testing of the behavioral effects of 5-HT1B autoreceptors.
5-HT1B receptor agonists are known to increase horizontal activity in the open field test [39, 40] . However, this well-known effect of 5-HT1B receptors is less valuable in testing the effect of GSK3b on 5-HT1B receptors because our previous study showed that GSK3b inhibitors did not affect this behavioral effect of 5-HT1B receptors [21] . Indeed, GSK3b knockout from serotonin neurons had no effect on anpirtoline-induced horizontal activity. Although not fully understood, previous studies suggest that this particular behavior is mostly regulated by 5-HT1B heteroreceptors [39, 54] and is affected by b-arrestins associated with 5-HT1B receptors [21] . In contrast, activation of 5-HT1A receptors by 8-OH-DPAT reduced horizontal activity. This finding is the same as reported by others [55] , supporting the validity of our test. Since this effect of 8-OH-DPAT was not altered in snGSK3b-KO mice, it does not distinguish between non-effectiveness of GSK3b on 5-HT1A autoreceptors or whether this is a function of 5-HT1A heteroreceptors. In addition, the opposite effects of 5-HT1B and 5-HT1A receptors on horizontal activity do not allow testing of the differential impact of GSK3b on a similar effect of the two subtypes of 5-HT1 receptors.
When center travel distance was calculated as the ratio of total horizontal travel distance, anpirtoline reduced center activity. This effect of anpirtoline likely involves activation of 5-HT1B autoreceptors since it was completely abolished in snGSK3b-KO mice. However, this appears to be a small effect since anpirtoline appeared to increase the total travel distance if the ratio was not analyzed. In addition, time in the center was also less affected by anpirtoline, which was possibly due to an overall increase in total horizontal activity. Additionally, this behavior could not compare the effect of GSK3b on 5-HT1B and 5-HT1A receptors, because 8-OH-DPAT was without an effect on center activity.
Interestingly, both anpirtoline and 8-OH-DPAT significantly reduced vertical activity in the open field test. This effect may represent an acute effect of these two 5-HT1 receptor subtypes in reducing exploration or provoking anxious behaviors [41] . Since the effect of anpirtoline was drastically altered in snGSK3b-KO mice, the result suggests that this behavioral effect of 5-HT1B receptors involves activation of its autoreceptors. In the absence of GSK3b in serotonin neurons, 5-HT1B autoreceptors are less functional [21, 22] , resulting in excessive exposure of sensitive neurons to unchecked serotonin signals. The time course of vertical movement recorded at each min of a 30-min posttreatment time revealed that snGSK3b-KO mice had a very different response pattern to anpirtoline, from an initial overreactivity to a transient suppression, but the response to anpirtoline was not sustained as seen in WT mice. This behavioral result builds on our previous impression that GSK3b does not function as an endogenous, full activator of 5-HT1B receptors; rather, GSK3b is a critical modulator for fine-tuning the activity of 5-HT1B receptors [8] . In striking contrast, the effect of 8-OH-DPAT on vertical activity was the same in WT and in snGSK3b-KO mice, again suggesting that GSK3b does not directly affect 5-HT1A receptor activity.
5-HT1B receptor agonists can reduce immobility in TST and forced swim test [42, 43] . This behavioral effect per se is thought to be a function of 5-HT1B heteroreceptors located within nonserotonin neurons [42] , but the effect usually requires high dosage of 5-HT1B receptor agonist when administered via a systemic route, presumably because simultaneous activation of 5-HT1B autoreceptors suppresses serotonin release and dampens the heteroreceptor-mediated behavioral effect. In reverse, enhancing serotonin release by ablating 5-HT1B autoreceptor action reportedly facilitates 5-HT1B receptor agonist-induced reduction of immobility [42, 43] . Utilizing the snGSK3b-KO mouse model that is proposed to affect only the function of 5-HT1B autoreceptors, we showed that disrupting the sensitivity of 5-HT1B autoreceptors to its agonist facilitates its anti-immobility effect. Indeed, the result obtained in snGSKb-KO mice was similar to our previous finding using GSK3 inhibitors, but better demonstrates an impact of GSK3b on 5-HT1B autoreceptors. We hypothesize that when 5-HT1B autoreceptor activity is suppressed in snGSK3b-KO mice, not only does anpirtoline mainly activates 5-HT1B heteroreceptors, but serotonin release is also enhanced in the absence of feedback inhibition by 5-HT1B autoreceptors. Consequently, serotonin neurotransmission is enhanced, which would then facilitate the anti-immobility effect of anpirtoline.
Overall, knockout of GSK3b in serotonin neurons provides a means to examine the activity and function of 5-HT1B autoreceptors without interfering with the activity of 5-HT1B heteroreceptors, which has been a challenge using conventional pharmacological approaches. Findings of this study provide new evidence that GSK3b modulates 5-HT1B autoreceptor-mediated signaling, physiology, and behavior, which entitles GSK3b as an active modulator of serotonin neurotransmission. This may partly explain the diverse effects of GSK3b in behaviors related to emotion, anxiety, and activity [47] . Noticeably, among reported in vivo effects of lithium [56, 57, 58, 59] , several earlier studies showed that lithium inhibits 5-HT1B receptors, and it was proposed that 5-HT1B receptors may be a therapeutic target of lithium [60] . With lithium being a GSK3 inhibitor [9] and our previously finding that lithium disrupts the direct interaction between GSK3b and 5-HT1B receptors in transfected cells [22] , it is probable that the effect of lithium on 5-HT1B receptor function is the result of its inhibition of GSK3b. Since lithium is a therapeutic agent in neuropsychiatric disorders [61] , finding of this study warrants future studies to investigate therapeutic approaches that disrupt the interaction between GSK3b and 5-HT1B autoreceptors to facilitate serotonin neurotransmission for the treatment of neuropsychiatric disorders. 
Materials and Methods
Chemicals
Animals
The Institutional Animal Care and Use Committee at the University of Alabama at Birmingham approved animal use in this study.
Homozygous GSK3b-flox/flox mice in a mixed C57BL/6 and 129 background [32] were cross-bred with ePet1-Cre mice on a C57BL/6 background [33] to generate homozygous GSK3b-flox/ flox:ePet1-Cre (snGSK3b-KO) and littermate wild type (WT, GSK3b-flox/flox) mice. Genotypes were confirmed by Polymerase Chain Reaction (PCR) of tail DNA using primers 59-GGG-GCAACCTTAATTTCATT and 59-TCTGGGCTATAGC-TATCTAGTAACG for GSK3b, and 59-AAAATTTGCCTG-CATTACCG-39 and 59-ATTCTCCCACCGTCAGTACG-39 for Cre ( Figure 1A ). TpH2 R439H knockin mice were described previously [11] .
Body Weight and temperature [62] were recorded from 4-12 weeks of age once per week between 15:00 and 17:00. Scout TM Pro (SP 601) scale (Chaus Corporation, Pine Brook, NJ USA) was used to measure body weight. Lubricated Thermalert TH-5 probe (Physitemp Instrument Inc., Clifton, NJ 07013) was inserted in the rectum for 15-20 sec to obtain stable recording of body temperature. Defecation [62] was recorded at 12 weeks of age by counting numbers of feces produced by each mouse during a 24-hour period.
Experimental mice were housed 4-5 per cage with free access to food and water in a 12-hour light/dark cycle animal facility. Adult (8-14 weeks old) male homozygous snGSK3b-KO mice and WT (GSK3b-flox/flox) mice were used for physiology, bioassays, and behavior tests. Since these mice were derived from GSK3b-flox/ flox breeders with a mixed strain background, to minimize the heterogeneous responses, each experiment was conducted using littermate snGSK3b-KO mice and WT mice.
Immunohistochemistry of TpH2 and GSK3b
Mice were anesthetized with ketamine and xylazine (100 mg/ kg:10 mg/kg) for transcardiac perfusion with 4% paraformaldehyde (PFA)/0.1M PBS (pH 7.4). Perfusion-fixed brains were immersed overnight in 30% sucrose, imbedded in the Tissue-Tek Optimal Cutting Temperature (O.C.T.) compound (Sakura Finetek, Torrance, CA), and frozen. Coronal and sagital brain sections (20 mm) were prepared on the Leica CM1850 cryostat slicer (Leica Microsystem, Buffalo Grove, IL). The coronal midbrain sections corresponding to Bregma: 23.6 mm to 25.2 mm were labeled with antibodies to GSK3b (BD Biosciences, Franklin Lakes, NJ) and to tryptophan hydroxylase (TpH2) (Novus Biologicals, Littleton, CO), and the sagital sections including the forebrain were labeled with anti-GSK3b. Sections were then reacted with the horseradish peroxidase-conjugated anti-mouse or anti-rabbit serum, treated with the Tyramide Signal Amplification (TSA) kit (Perkin Elmer, Waltham, MA), and counter-stained with the nuclear marker Hoechst 33,258 (SigmaAldrich, St. Louis, MS). Immunofluorescence of brain sections was viewed and captured with the Leica DM6000B digital confocal microscope (Leica Microsystem, Buffalo Grove, IL). The number of TpH2-positive cells and GSK3b/TpH2 co-stained cells were counted manually by an unbiased observer blind to genotypes. Photographed fields (63x magnification) from each of the ventral, dorsal, and dorsal-lateral raphe nucleus were counted. Three animals from each genotype with 1-2 brain slices from each animal were used for cell counting. Only cells with a nucleus (Hoechst 33,258 stained) are included for cell counting. GSK3 expression in serotonin neurons were expressed by co-stained cells as percent of total TpH2-positive cells in each area. Cell counts were confirmed by counting each field twice from the left to the right.
Immunohistochemistry of brain serotonin
All mice used in this experiment were 3 months old females, including TpH2 R439H knockin homozygote and littermate WT [11] , and snGSK3â-KO and littermate WT mice. After perfusion fixation as described above, sagittal sections (50 mm) of the frozen brain were made by vibratom the day of staining. The selected slices were incubated in PBS, 3% BSA and 0,5%Tri-ton100X, overnight at 4uC in the presence of rabbit antiserotonin antibody (1:100, S5545 Sigma-Aldrich). After washing in PBS (3 times, 10 min), the sections were incubated for 2 hours at room temperature with anti-rabbit IR800CW from (1:1000, Licor, Lincoln, NE). They were washed and mounted on slides with Prolong Gold. Tissue sections were imaged at a 21 mm resolution with the Odyssey Licor imager [35] . Comparative quantification was always made on the same scan and regions of interest (ROI) used for quantification of the same area for the same brain region from section to section. Six tissue sections from two animals of each genotype (3 sections per animal) were used for analysis.
Raphe serotonin neuron firing
For electrophysiology experiments, WT and snGSK3b-KO mice were euthanized by decapitation and brains were removed and blocked in cold sucrose-substituted saline solution [36, 63] . Briefly, coronal midbrain slices (200 mm) containing the dorsal raphe nucleus were sliced on a Vibroslicer at 4-10uC and maintained in 50% sucrose saline/50% normal saline solution for 10 min at room temperature followed by 100% normal saline solution maintained at 3460.5uC. Neurons were visualized with an Axio Examiner microscope (Carl Zeiss Inc., Thornwood, NY) equipped for near-IR digital image correlation. Extracellular patch electrodes with a pipette resistance of 3 to 4 MV were filled with filtered, normal Hepes solution. Firing rate frequency was measured as the average of a 30-sec recording. All neurons were treated first with serotonin (40 mM) for 2 min, followed by at least 10 min washout to allow for complete firing rate recovery, and then treated with anpirtoline (10 mM) or 8-OH-DPAT (1 mM) for 2 min. For high potassium condition [37] , neurons were given potassium chloride (KCl, 10 mM) for 2 min, followed by a 2 min application of anpirtoline (5 mM). All solutions contained 3 mM phenylephrine hydrochloride and 24 mM L-tryptophan to maintain the spontaneous firing rate in the absence of noradrenergic tone and tryptophan availability [64] .
Cyclic AMP (cAMP) assay
Cerebral cortical slices from WT and snGSK3b-KO mice were prepared as previously described [22] , followed by incubation with pharmacological agents. Cortical slices were treated with or without 5-HT1B receptor antagonist SB224289 or 5-HT1A receptor antagonist WAY100635 for 15 min before treatment with 5-HT1B receptor agonist anpirtoline or 5-HT1A receptor agonist 8-OH-DPAT for 30 min, followed by forskolin (10 mM) treatment for 15 min. After pharmacological treatments, cortical slices were lysed in a buffer containing 2.5% dodecyltrimethylammonium bromide, and the level of cAMP in the lysate was measured using an enzyme immunoassay kit (Direct BioTrak, Amersham/GE). Cyclic AMP production was calculated against a cAMP standard, and normalized by total protein content in each sample (pmol/mg) [21, 22] .
Serotonin release
Cerebral cortical slices from WT and snGSK3b-KO mice were prepared as previously described [21] . Cortical slices were labeled with [ 3 H]-serotonin (1.3 mCi/ml) in Krebs buffer [121 mM NaCl, 1.2 mM MgCl 2 , 1.3 mM CaCl 2 , 25 mM NaHCO 3 , 1.0 mM NaH 2 PO 4 , 10 mM glucose, 13.5 mM KCl, 50 mM l-tryptophan, 50 mM l-tyrosine, 10 mM nomifensine malate (dopamine reuptake inhibitor), and 10 mM imipramine (serotonin reuptake inhibitor)] with 95% O 2 and 5% CO 2 at 37uC for 30 min, transferred into the perfusion chambers (10,11 slices/chamber) and superfused with aerated (95% O 2 and 5% CO 2 ) and preheated (37uC) Krebs buffer. The flow rate was kept at 0.5 ml per minute by a BIO-RAD multichannel peristaltic pump (Econo Pump, USA). Beginning at 61 min of perfusion, the superfusion fluid was collected at 0.5 ml/min. Brain slices were stimulated with potassium chloride (KCl, 50 mM) at 63 min and at 83 min, respectively. For anpirtoline or 8-OH-DPAT treatment, the perfusion buffer was replaced at 78 min by fresh Krebs buffer containing anpirtoline or 8-OH-DPAT (5 mM). Collection of superfusion fluid continued until 98 min. At the end of the experiment, the brain slices from each chamber were collected and homogenized in 200 ml of 1N HCl containing 0.1% Triton X-100. Superfusion fluid from each fraction and tissue homogenate (200 ml) was mixed with 3 ml scintillation liquid (Universol, MP), and radioactivity was counted by a scintillation spectrometry (Multi-Purpose Scintillation Counter, LS-6500, Beckman). To calculate [ 3 H]-serotonin release, the radioactivity from fractions collected at 61-63 min were averaged as a baseline for the first KCl stimulation, and fractions at 81-83 min were averaged for the second KCl stimulation. The radioactivity of all fractions was calculated as: CPM x 100/baseline CPM. Data were processed by OringPro 8.1, and potassium-evoked [ 3 H]-serotonin release was represented by the peak area surrounded by the fitting line and baseline. Effect of a drug was determined by the ratio of the second overflow (P2) to the first overflow (P1) [21] .
Rotarod Test
Rotarod was used to measure motor coordination [65] . Mice were trained on the Acceler Rota-Rod (Ugo Basile, Collegeville, PA) with a fixed speed (10 rpm) for 10 min each time, 3 times per day for 3 continuous days. Fourteen days later the same mice were trained again on the rotarod with an accelerating speed 3 times in one day. The motor ability was tested on the next day with the same accelerating speed. Latency to drop from the rotarod was recorded as the index of motor ability.
Open field test
The locomotor activity was tested in a plexiglas open field (Med Associates, St. Albans, VT), and activity was monitored using the activity monitoring software (Med Associates, St. Albans VT) [21, 66] . Mice were allowed to habituate in the open field for 15 min before drug treatment, followed by an additional 30 min testing in the open field. Activity was measured by recording horizontal activity, center activity, and vertical activity. The posttreatment horizontal activity was calculated as the ratio of posttreatment over pre-treatment horizontal travel distance. The posttreatment center activity was calculated as the distance traveled to the center over total horizontal travel distance. The vertical activity was recorded by the total numbers of rearing.
Tail suspension test (TST)
TST was conducted using an automated testing system (Med Associates Inc, St. Albans, VT) [21, 66] . Movement is measured for 6 min, and the immobility time was recorded with the Med Associates software and calculated as the time the force of movement was below a preset threshold. Immobility was recorded as each 2-min bin and the last 4 min of testing. For drug treatment, anpirtoline or saline was given for 30 min before testing.
Data Analysis and Statistics
All experiments and treatments were repeated for statistical analysis. Data were analyzed with Student's t-test, one-way or twoway analysis of variance (ANOVA) with LSD post hoc analysis for multiple comparisons, two-way repeated measures ANOVA with Sidak post hoc analysis for multiple comparisons, or mixed models where appropriate. For repeated measures, if sphericity was violated (indicated by a significant Mauchly's W), a GreenhouseGeisser adjustment of the degrees of freedom was employed. Values are expressed as mean 6 SEM and are considered significant when p,0.05. SPSS 13.0.0.0, PASW 18.0, and SAS 9.2 software were used for statistical analysis.
